Elanco Animal Health Incorporated Common Stock (ELAN)
Elanco Animal Health Incorporated is a global company focused on developing, manufacturing, and marketing products for animal health. It specializes in veterinary pharmaceuticals, vaccines, and nutritional products aimed at enhancing the health and well-being of pets and livestock. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a broad customer base across multiple markets, emphasizing innovation in animal healthcare.
Company News
The global pet cancer therapeutics market is projected to grow from $493 million in 2025 to $1.15 billion by 2034, driven by increasing pet cancer awareness, advanced veterinary treatments, and growing pet humanization trends.
Elanco Animal Health reported Q2 2025 earnings with revenue of $1,241 million, beating estimates. The company saw strong performance in pet and farm animal health segments, driven by innovative product launches, though profitability metrics weakened due to higher operating expenses.
Elanco Animal Health reported a strong Q1 2025 with adjusted EPS beating guidance and consensus. However, the company provided a soft Q2 EPS guidance, leading to a mixed sentiment. The company raised its full-year 2025 revenue guidance but maintained its adjusted EBITDA and EPS ranges.
Elanco Animal Health has divested its aqua business to Merck Animal Health for $1.3 billion, enabling the company to focus on pet health and livestock sustainability while reducing its debt burden.
The deal “allows us to prioritize our investments in larger markets with greater earnings potential over the medium and long term, while creating balance sheet flexibility,” Elanco Animal Health said in a statement.